SUPPLEMENTARY FIGURES AND TABLES



www.impactjournals.com/oncotarget/

Oncotarget, Supplementary Materials 2016



4

WW

PCL

SMM

ż

IGUS

SMM

WW

РС

Supplementary Figure S1: Box plot of lncRNAs resulting from The Jonckheere–Terpstra test.

ż

NGUS

- MM

- L

ż

NGUS

SMM

	PAIRED t-TEST		Inc-LF	RA7-1
IncRNA	E vs REC	400		
	<i>p</i> -value	300		
Inc-ANGPTL1-3	0.3	250		
Inc-CPSF2-2	0.027	200		
Inc-DLX5-4	0.89	100		
Inc-DNAJC16-1	0.94	50		
Inc-HSFY2-10	0.8	0	Е	REC
Inc-IRF2-3	0.58			
Inc-KIF20B-7	0.85	600	Inc-S	ENP5-4
Inc-LRRC47-1	0.007	500	· · · · · · · · · · · · · · · · · · ·	
Inc-MC2R-2	0.98	400		
Inc-PNRC1-1	0.87	300	· · · · ·	
Inc-RALGAPB-1	0.12	200		
Inc-RLIM-6	0.97	100		
Inc-SAFB2-3	0.92	0	E	REC
Inc-SENP5-4	0.04	100	Inc-CPSF2-2	
Inc-SERPINC1-1	0.069	160 — 140 —		
Inc-SNX29P2-3	0.69	120		
Inc-STOM-7	0.66	100		
Inc-VKORC1L1-3	0.98	80		
Inc-WDR11-7	0.23	40		
Inc-WHAMM-2	0.99	20		
Inc-ZC3H12B-10	0.18	0	Е	REC

Supplementary Figure S2: Three out of 21 lncRNAs progressively increased/decreased in association with the stages of the desease are also significantly deregulated in a paired cohort of 19 MM and PCL.



Supplementary Figure S3: Positive Pearson's correlation between Inc-SPRYD7-1 and miR-15a or miR-16-1 expression levels. MiRNA expression data was available for 125 samples out of our series (GSE70254 and GSE73452) generated using GeneChip® miRNA 3.0 Array (Affymetrix Inc., Santa Clara, CA) as previously described (Calura et al 2015)



Supplementary Figure S4: Database quality control. A-B. Normalized unscaled standard error (NUSE) plot and relative log-expression (RLE) distribution plots. **C.** Principal Component analysis (PCA) plot.

Supplementary Table S1: Modulated lncRNAs between N controls and MGUS, sMM, MM or PCL patients.

See Supplementary File 1

Supplementary Table S2A: Modulated lncRNAs between HD+ and HD- MM patients.

See Supplementary File 1

Supplementary Table S2B: Modulated lncRNAs between t(11;14)+ and t(11;14)- MM patients.

See Supplementary File 1

Supplementary Table S2C: Modulated lncRNAs between t(4;14)+ and t(4;14)- MM patients.

See Supplementary File 1

Supplementary Table S2D: Modulated lncRNAs between MAF+ and MAF-MM patients.

See Supplementary File 1

Supplementary Table S3: List of 518 differentially expressed genes in MALAT quartile I vs quartile IV by SAM analysis at high stringency level (median FDR=0, 90th perc FDR=0). Genes are ordered according to SAM score, the fold change (FC) is also reported.

See Supplementary File 1

Supplementary Table S4: List of the significantly enriched pathways for the 518 differentially expressed genes, by Toppgene suite analysis.

See Supplementary File 1

Supplementary Table S5: Selected gene sets significantly up- and down-regulated in MALAT1 quartile IV versus I by GSEA analysis. Genes contributing to the core enrichment in each gene set are indicated in bold.

See Supplementary File 1

Supplementary Table S6: Sequence-specific SYBR green qRT-PCR primers.

See Supplementary File 1